OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
Launch of VerteGlide System: OrthoPediatrics Corp. has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, designed to treat Early Onset Scoliosis in children, marking the company's 80th system for pediatric musculoskeletal issues.
Innovative Treatment Commitment: The new technology aims to correct spinal deformities while minimizing the need for repeat surgeries, reflecting OrthoPediatrics' commitment to improving treatment options for vulnerable pediatric patients with scoliosis.
Trade with 70% Backtested Accuracy
Analyst Views on KIDS
About KIDS
About the author
OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products
New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.
Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.
Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.
Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.
What Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?
Analyst Price Target Changes: OrthoPediatrics' consensus analyst price target has been lowered from $26.29 to $24.14, reflecting a cautious outlook amid mixed research commentary and short-term challenges.
Bullish Analyst Sentiment: Despite the lowered price targets, several firms maintain positive ratings, emphasizing confidence in the company's core business and long-term prospects, particularly in high-margin product lines.
Bearish Analyst Concerns: Some analysts express caution, citing near-term headwinds and lower guidance, with notable reductions in price targets and concerns over revenue visibility impacting future growth expectations.
Company Developments: OrthoPediatrics announced an intangible asset impairment of $2.27 million, received FDA approval for a new system, and revised its 2025 revenue guidance downward, while also reporting improved net profit margins.
Understanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations
Analyst Ratings Overview: OrthoPediatrics has received mixed ratings from analysts, with 6 bullish, 3 somewhat bullish, and no bearish ratings in the last 30 days, reflecting a shift in sentiment compared to previous months.
Price Target Adjustments: Analysts have lowered their 12-month price targets for OrthoPediatrics, with an average target now at $27.44, down from $36.44, indicating a decrease in expected stock performance.
Financial Performance Metrics: The company has shown a revenue growth rate of approximately 15.68% and maintains a net margin of -11.64%, outperforming industry standards in terms of financial performance.
Debt Management and Ratios: OrthoPediatrics has a debt-to-equity ratio of 0.27, which is below industry norms, suggesting a solid financial structure and effective management of shareholder equity.
Needham Keeps Buy Rating on OrthoPediatrics, Reduces Price Target to $26
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
BTIG Affirms Buy Rating for OrthoPediatrics, Keeps $23 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
OrthoPediatrics and iotaMotion Partner Receive FDA Clearance
- FDA Clearance Expansion: iotaMotion's iotaSOFT® Insertion System has received FDA 510(k) clearance for use in children aged four and older, significantly broadening access to robotic-assisted cochlear implantation and expected to enhance OrthoPediatrics' market share in the pediatric ENT sector.
- Deepening Strategic Partnership: The collaboration between OrthoPediatrics and iotaMotion aims to integrate advanced robotic technology into pediatrics, improving the efficiency and consistency of cochlear implant surgeries, thereby solidifying its leadership position in pediatric healthcare.
- First Adopting Hospital: Cincinnati Children's Hospital becomes the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S., marking widespread recognition of this technology in pediatrics and likely encouraging further hospital adoption.
- Broad Market Prospects: OrthoPediatrics plans to leverage this technology to expand its impact in pediatric care, supported by a capital-light business model and diverse revenue streams, addressing unmet pediatric needs effectively.
OrthoPediatrics Corp. Enhances Specialty Bracing Line with Launch of Two New Products
New Product Launches: OrthoPediatrics Corp. has expanded its OrthoPediatrics Specialty Bracing portfolio with the introduction of the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, aimed at treating Developmental Dysplasia of the Hip (DDH) in children aged three years and younger.
Collaboration with Experts: The new products were developed in collaboration with leading pediatric hip specialists, enhancing treatment options for patients and their families.
Commitment to Pediatric Care: Joe Hauser, President of the Specialty Bracing division, emphasized the company's focus on organic product development and its commitment to improving pediatric orthopedic care through innovative solutions.
Comprehensive Product Offering: Founded in 2006, OrthoPediatrics markets over 85 products across various pediatric orthopedic categories, including trauma, deformity, scoliosis, and sports medicine, serving both the U.S. and international markets.
What Factors Might Influence the OrthoPediatrics Narrative Following Analyst Updates?
Analyst Price Target Changes: OrthoPediatrics' consensus analyst price target has been lowered from $26.29 to $24.14, reflecting a cautious outlook amid mixed research commentary and short-term challenges.
Bullish Analyst Sentiment: Despite the lowered price targets, several firms maintain positive ratings, emphasizing confidence in the company's core business and long-term prospects, particularly in high-margin product lines.
Bearish Analyst Concerns: Some analysts express caution, citing near-term headwinds and lower guidance, with notable reductions in price targets and concerns over revenue visibility impacting future growth expectations.
Company Developments: OrthoPediatrics announced an intangible asset impairment of $2.27 million, received FDA approval for a new system, and revised its 2025 revenue guidance downward, while also reporting improved net profit margins.
Understanding OrthoPediatrics: Key Takeaways from 9 Analyst Evaluations
Analyst Ratings Overview: OrthoPediatrics has received mixed ratings from analysts, with 6 bullish, 3 somewhat bullish, and no bearish ratings in the last 30 days, reflecting a shift in sentiment compared to previous months.
Price Target Adjustments: Analysts have lowered their 12-month price targets for OrthoPediatrics, with an average target now at $27.44, down from $36.44, indicating a decrease in expected stock performance.
Financial Performance Metrics: The company has shown a revenue growth rate of approximately 15.68% and maintains a net margin of -11.64%, outperforming industry standards in terms of financial performance.
Debt Management and Ratios: OrthoPediatrics has a debt-to-equity ratio of 0.27, which is below industry norms, suggesting a solid financial structure and effective management of shareholder equity.
Needham Keeps Buy Rating on OrthoPediatrics, Reduces Price Target to $26
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.
BTIG Affirms Buy Rating for OrthoPediatrics, Keeps $23 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.
